Self-reported compliance with a malaria chemoprophylaxis regimen of proguanil (PG) plus chloroquine (CQ) was assessed in a cohort of 547 Dutch travellers who visited a single travel clinic when travelling to various areas endemic for falciparum malaria. 503 (92%) had taken PG/CQ prophylaxis, but only 326 (60%) reported regular and uninterrupted use throughout the journey and 4 weeks afterwards. Compliance differed by travel destination and was 45% in South America, 52% in West Africa, 53% in South-east Asia, 60% in the Indian Subcontinent and 78% in East Africa. Parasitologically confirmed falciparum malaria occurred in 5 travellers (0.9%), including 3 of 24 non-compliant travellers to West Africa (12.5%). Apart from destination, independent risk factors for non-compliance were young age, extensive travel experience and adventurous travel. Compliance with protection against mosquito bites was 80% for wearing long-sleeved shirts and long-legged trousers after sunset, 73% for use of repellents, 56% for sleeping under bednets and 37% for keeping the sleeping quarters free of mosquitoes. Although 440 travellers (80%) reported to have taken two or more of these measures at least once, only 88 (16%) had done so on a daily basis. Daily use of bednets was reported more frequently among subjects who were non-compliant with chemoprophylaxis. Compliance regarding malaria chemoprophylaxis should be improved, particularly in high-risk areas such as Sub-saharan Africa, with extra attention to young, adventurous travellers. More emphasis should be placed on prevention of Anopheles bites.
Introduction
Among travellers to endemic areas, compliance regarding malaria chemoprophylaxis is generally poor, ranging from 32 to 74% depending on the definitions used (Phillips-Howard et al. 1986; Lobel et al. 1987 Lobel et al. , 1990 Coole et al. 1989; Steffen et al. 1990; Kollaritsch & Wiedermann 1992; Gyorkos et al. 1995) . Malaria chemoprophylaxis has been shown to have a low costto-benefit ratio compared to other prophylactic interventions in travellers (Behrens & Roberts 1994) , and several studies suggested increased risks of malaria in non-compliant travellers (Lobel et al. 1987; Gyorkos et al. 1995; Phillips-Howard et al. 1990; Behrens & Curtis 1993) . Knowledge of factors that predict noncompliance is important as it may be used to increase compliance by improving pre-travel information. Such risk factors have been studied among European and North American travellers on return flights form Kenya and several West African countries, and have included young age, longer travel duration, previous travel to tropical destinations, visits of friends or family as travel purpose, occurrence of adverse reactions and use of proguanil (Lobel et al. 1990; Steffen et al. 1990 ). However, as these studies involved travellers from various countries using different chemoprophylaxis regimens, the results may in part reflect differences in pre-travel advice and prescription. In addition, data on the use of chemoprophylaxis for other travel destinations are limited. Although here malaria risks for travellers are relatively low Steffen et al. 1990 ), most authorities advocate chemoprophylaxis for travel to malaria endemic areas outside Sub-saharan Africa (World Health Organization 1991; Bradley & Warhurst 1995) .
Anti-mosquito measures also contribute to the prevention of malaria in travellers. Although the application of such measures has been assessed in some studies (Steffen et al. 1990; Gagneux et al. 1996) , little is known about their relation with the use of chemoprophylaxis, e.g. whether travellers who are non-compliant with chemoprophylaxis take antimosquito measures instead, or rather tend to be non-compliant with any advice on malaria prevention at all.
We assessed in a prospective study the compliance with a malaria chemoprophylaxis regimen of proguanil and chloroquine, and factors predictive of noncompliance, among Dutch travellers who visited one single travel clinic for journeys to various malariaendemic areas. As a secondary objective, we studied the self-reported use of measures to prevent Anopheles bites and its association with chemoprophylaxis use.
Subjects and methods

Study design and inclusion criteria
The study was part of a larger cohort study of health risks in travellers, conducted at the travel immunization clinic of the Amsterdam Municipal Health Service. Between February 1991 and February 1992, all Dutchspeaking clients у15 years who intended to travel to areas endemic for falciparum malaria for 1-13 weeks were asked to participate. The study was approved by the Board of Medical Ethics of the Muncipal Health Service. All subjects were routinely prescribed proguanil 100 mg daily and chloroquine 300 mg weekly. Following a change in the Dutch recommendations, the daily proguanil dose was doubled to 200 mg in the subjects enrolled after July 1991. All travellers were first seen by a physician or trained nurse for immunizations and malaria advice. They received standard verbal information on chemoprophylaxis and protection against Anopheles bites, and a leaflet providing details of the chemoprophylaxis regimens and anti-mosquito measures. This stressed specifically the need to continue chemoprophylaxis for 4 weeks after return from the malarious area, to wear long-sleeved shirts and longlegged trousers after sunset, to use repellents on the uncovered parts of the skin after sunset, to keep the sleeping quarter free of mosquitoes, and to sleep under bednets. Eligible travellers were then asked to participate in the study, and seen by another nurse for registration, a serum sample and answering a questionnaire on medical history and travel plans. Study subjects visited the clinic again within 6 weeks after return from the endemic area for serum sampling and to fill in a second questionnaire that addressed, among other items, travel itinerary, use of chemoprophylactics, symptoms ascribed to the chemoprophylaxis, episodes of falciparum malaria and application of anti-mosquito measures.
Definitions
Compliance with the chemoprohylaxis regimen was recorded retrospectively by self-reported use and defined as regular and uninterrupted use of both proguanil and chloroquine until the post-travel interview or until 4 weeks after return if the post-travel interview was held more than 4 weeks after return (Lobel et al. 1990 ). The operational definition of regular and uninterrupted use was not having missed more than one day-dose per week on average for proguanil, and not having missed any dose of chloroquine. Compliance regarding protection against mosquito bites was recorded as self-reported use and defined as having applied two or more of the four measures mentioned in the leaflet. (Cobelens et al. 1997) . Travel destinations were grouped into 5 regions that corresponded to the classification used by the World Health Organization (1991). Travel duration was recorded as the total travel time in weeks in areas meeting the enrolment criteria. Adverse effects were recorded as any symptom ascribed to chemoprophylaxis by the study subject.
Data analysis
To prevent selection and recall bias, subjects who changed their travel itinerary in such way that they did not meet the inclusion criteria afterwards or who had their post-travel interview more than 6 weeks after return were exluded from the analysis. Also excluded were subjects who travelled to more than one geographical region, as this would have impaired analysis by destination. Chi-square ( 2 ) tests were used for significance testing of associations between categorical variables; Yates continuity correction was applied for all 2 ϫ 2 tables. Effects were expressed as odds ratios. Independent risk factors for noncompliance were identified by logistic regression analysis (Hosmer & Lemeshow 1989) . Variables of interest were sex, age, travel experience, education level, destination and purpose and style of travel. The variables duration of travel (р 3 weeks vs Ͼ 3 weeks), travel season (rainy vs dry), degree of mobility (one place vs travelling around), daily proguanil dose, reporting of side-effects and time interval between return and the post-travel interview were treated as potential confounders (Lobel et al. 1990; Steffen et al. 1990) . Confounding was assumed when exclusion from the regression model resulted in more than 20% change in any estimate for the variables of interest. The contribution of the variables to the model was assessed by the likelihood ratio test for excluding the variable from the final model; the model goodness-of-fit was assessed by the Hosmer-Lemeshow test (Hosmer & Lemeshow 1989) . Destination was treated as a 5 category variable; with the region where compliance was highest as the reference category.
Results
Study population
Of 629 subjects who were enrolled initially, post-travel data were available for 608 (96.7%). After exclusion of 39 subjects (6.2%) who had spent less than one week in endemic areas or visited more than one geographical region, 21 subjects (3.3%) who had their post-travel visit more than 6 weeks after return, and one (0.2%) with incomplete data regarding chemoprophylaxis, data of 547 subjects (87.0%) were analysed. Characteristics of the study population are given in Table 1 . 28.5% were Ͻ 30 years of age; 11.5% were 50 years or older. Travel duration was 1-3 weeks for 36.9%. South-east Asia was the region visited most; 4 countries (Indonesia, India, Kenya and Thailand) accounted for 54% of the destinations. Travel experience differed significantly with travel purpose: 51% of business travellers reported more than 5 previous journeys compared to 22% and 20% for holiday travellers and subjects visiting friends or relatives, respectively ( 2 test, P Ͻ 0.001). Of 47 subjects visiting friends or relatives, 9 (19.2%) had spent their childhood in the tropics. The post-travel interview took place 15-28 days after return for 86.2%, within 14 days for 6.0%, and after 28 days for 7.8% of the study subjects, respectively.
Use of chemoprophylaxis
Although 503 travellers (92.0%) took both proguanil (PG) and chloroquine (CQ) at least once, only 326 (59.6%) reported full compliance regarding chemoprophylaxis. Table 2 shows the contribution of the various causes of non-compliance for PG, CQ, and both drugs combined. Early discontinuation of chemoprophylaxis after return (within 4 weeks or before the post-travel interview) was observed most frequently and reported for either PG or CQ by 123 of all 547 travellers (22.5%), representing 55.7% of the 221 who were classified as non-compliant. There were no significant differences between PG and CQ regarding overall compliance (364/547 or 66.5%, and 343/547 or 62.7%, respectively) and individual causes of non-compliance. Adverse effects of chemoprophylaxis were reported by 146 travellers, representing 29.0% of subjects who took either PG or CQ at least once.
The proportion of non-compliance differed significantly among destinations (Table 3 ). The highest compliance was reported by travellers to East Africa (77.7%) and the lowest by travellers to South America (45.3%). For East and West Africa together, compliance was 70.2% (95% CI 63.3-76.5%).
Reasons for early discontinuation during or after travel were obtained from 164 of 185 (88.6%) travellers. The reason given most frequently (72, 43.9%) was that it was deemed unnecessary to continue prophylaxis because of the low or absent risk during (the last) part of the journey; in 12 of these cases it was stated that no mosquitoes had been seen. Another 20 (12.2%) had stopped on advice by others, including travel guides, health authorities in the country concerned (e.g. Thailand) and doctors. Adverse reactions were reason to discontinue for 19 travellers (11.6%), and negligence for 28 (17.1%). Other reasons mentioned (all less than 5%) were lack of awareness of the need to continue, loss of tablets, bad taste of the tablets, insufficient amounts prescribed, fear of developing adverse effects and (possible) pregnancy. -tests for differences between proguanil and chloroquine. 1 either proguanil or chloroquine, 2 for proguanil: missed more than one day-dose per week on average; for chloroquine: missed one or more dose. 
Risk factors for non-compliance with the chemoprohylaxis regimen
Falciparum malaria
Parasitologically confirmed falciparum malaria was reported by 5 of 547 travellers (0.9%); in all 5 the posttravel serum tested positive in the IFAT whereas the pretravel sera remained negative. Travel destinations had been West Africa for 3, East Africa for 1 and South America for 1 (Suriname). The 3 travellers from West Africa reporting falciparum malaria had all stopped their prophylaxis prematurely; test P-values for differences between compliant and non-compliant subjects.
3 2 test for trend (df ϭ 1): p ϭ 0.37 (NS).
Table 5
Application of protective measures against mosquito bites among 547 Dutch travellers to areas endemic for falciparum malaria by compliance with a proguanil/chloroquine chemoprohylaxis regimen the other two reported complete compliance. The incidence risk for non-compliant travellers in West Africa was 3/24 (12.5%; 95% CI 2.7-32.4%). Table 5 shows the use of the 4 measures against mosquito bites that were studied. When assessed as measures used at least some of the time, wearing clothing covering arms, feet and legs after sunset was reported most frequently (80.1%), followed by use of repellents (73.5%), sleeping under a bednets (55.9%) and keeping sleeping quarters free of mosquitoes (37.3%). Compliance regarding protective measures, defined as having applied at least two measures once, was reported by 440 travellers (80.4%), and did not show association with compliance with the chemoprophylaxis advice ( 2 test, P ϭ 0.408). When compliance was defined as the application of at least two measures during every night throughout the journey, only 88 subjects (16.1%) were compliant. There were no significant associations between the application of individual protective measures and compliance with chemoprophylaxis (Table 5 ) except for the use of bednets; subjects who were compliant regarding chemoprophylaxis were less likely to have used bednets every night. When restricted to compliance during travel, a significant association was again only observed with the use of bednets ( 2 test, P ϭ 0.002).
Prevention of mosquito bites
Discussion
In this prospective study we found an overall rate of full compliance with the PG/CQ chemoprophylaxis regimen of only 60%, but with considerable differences across destinations. Compliance among travellers to East Africa (95% CI 71-85%) compared favourably with that reported from a study using similar definitions of compliance (Steffen et al. 1990 ) among European tourists in this region (57%). However, compliance among travellers to West Africa was much lower (95% CI 39-66%), as were compliance rates for destinations outside Africa, ranging from 45 to 60%. This suggests that compliance rates found in studies of travellers to East Africa overestimate the true compliance in other regions of the world. These studies may overestimate compliance anyway, as self-reported compliance with chloroquine prophylaxis has been shown to be unreliable in 14-22% of malaria patients (Wetsteyn & De Geus 1995; Behrens et al. 1992) . This study also showed 80% compliance with written advice on anti-mosquito measures (i.e. at least 2 antimosquito measures taken). This may seem high, but it remained unknown whether these had always been taken when appropriate, and only 16% had taken at least two measures throughout the journey. Our data do not indicate that those travellers who are non-compliant with chemoprophylaxis are also the ones that are noncompliant with other preventative advice. On the contrary, daily use of bednets was reported more often by subjects who were non-compliant regarding chemoprophylaxis. Even though this related to only 20% of non-compliant subjects, this indicates that some travellers do take appropriate anti-mosquito measures in lieu of chemoprophylaxis.
These data indicate that the verbal and written information given to the travellers in this study was insufficient to induce practices in accordance with the prophylactic guidelines. This is probably not due to lack of understanding, as compliance was not predicted by education level, and Gagneux et al. (1996) found no association between knowledge about malaria and compliance with the chemoprophylaxis regimen. Apart from destination, 3 risk factors that may be of importance in pre-travel health advice were shown to be indepently predictive. Young age and extensive travel experience have been identified as risk factors by others (Lobel et al. 1990; Steffen et al. 1990 ); this study also indicates that compliance is better in subjects over 50 years of age. The association of non-compliance with extensive previous travel to the tropics suggest that persons who travel frequently either assess their risk of malaria themselves, relying on their knowledge and experience, or tend to neglect these risks. A third predictive factor that we identified is self-organized travel, i.e. travellers on an organized trip are more likely to be compliant. This suggests that travel on organized tours (usually group travel) increases compliance by social stimulation. The alternative explanation that travellers who embark on organized tours tend to avoid risks in general is less likely, as the association was absent for non-compliance due to early discontinuation after return home. We did not confirm the increased risk of non-compliance in travellers visiting friends or relatives found by Lobel et al. (1990) . This is probably due to differences in study populations, as in the latter study the majority of such travellers originated from the country they visited, whereas this was less than 19% in ours.
Half of all non-compliance was due to early discontinuation after return, and more than half of the travellers who stopped their chemoprophylaxis prematurely did so because they did not consider it necessary to continue, either on their own account or advised by others. This suggests that the low compliance rates have different meanings for different travel destinations. In East and particularly West Africa, falciparum malaria is highly endemic and more or less evenly distributed; malaria risks for travellers here are among the highest in the world (Steffen et al. 1990; Phillips-Howard et al. 1990) . Most travellers to these areas who do not find it necessary to continue their chemoprophylaxis until at least 4 weeks after return are misinformed about their malaria risk, as is reflected by our finding that 12.5% of non-compliant travellers to West Africa acquired falciparum malaria. Popular myths, such as that no malaria risk exists if no mosquitoes are seen or that chloroquine is harmful during pregnancy, can have grave consequences in these areas.
In many areas outside Sub-Saharan Africa however, falciparum malaria has a focal distribution, often with marked seasonal variation, and the risk for travellers is substantially lower ). National recommendations regarding malaria chemoprophylaxis, such as followed in our study, do often not account for these local differences in endemicity and infection risks. Therefore travellers to these areas may have had a very low malaria risk during at least part of the journey, and early discontinuation of chemoprophylaxis may have actually been an epidemiologically sound decision. Considering the low compliance rates, one could argue whether these travellers should have been prescribed chemoprophylaxis in the first place. Relying on antimosquito measures could be a safe alternative for most travellers to these destinations, provided that they seek medical treatment if fever develops. However, such a policy requires more detailed data on malaria risks to travellers in various parts of the world and better compliance with advice on anti-mosquito measures.
We conclude that the compliance with malaria chemoprophylaxis should be improved in travellers to areas with high risks of infection, such as most of SubSaharan Africa. The need of continuing the chemoprophylaxis should be made clear, and popular myths should be addressed. For this, new methods of travellers' education need to be developed that should be based on data from in-depth studies of travellers' motivations to take preventative measures. Extra attention should be paid to young, independent travellers, and to persons travelling frequently who may underestimate their risk of malaria on the basis of their experience in low-risk areas or seasons.
In some other areas however, low compliance may in fact be justified by the low risks of malaria and prevention of Anopheles bites combined with early diagnosis and treatment of clinical malaria could be a safe alternative. In any case, more emphasis should be placed on anti-mosquito measures.
